Drug Profile
Metopimazine - Neurogastrx
Alternative Names: NG 101Latest Information Update: 05 Apr 2023
Price :
$50
*
At a glance
- Originator Neurogastrx
- Class Antiemetics; Gastrokinetics; Phenothiazines; Piperidines
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine receptor modulators; Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastroparesis
- No development reported Gastrointestinal disorders
Most Recent Events
- 25 Feb 2023 Neurogastrx completes a phase II trial in Gastroparesis in USA (PO) (NCT04303195)
- 28 Mar 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in USA
- 14 Dec 2020 Chemical structure information added